Charles River Laboratories Intl. Inc vs Datadog Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $283.29 (market cap $13.46B), while Datadog Inc trades at $250.42 (market cap $88.61B). The key difference: Datadog Inc is far larger — about 6.6× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Datadog Inc nearer its low. Which is the better fit depends on your goals.
| CRL | DDOG | |
|---|---|---|
Market Cap | $13.46B | $88.61B |
Sector | Health | Technology |
52-Week High | $282.00 | $288.15 |
52-Week Low | $145.57 | $102.62 |
Enterprise Value | $16.30B | $84.90B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $277.00, up 3.56% on the day and near its 52-week high of $277.07, reflecting strong bullish momentum. The stock exhibits positive technical signals with moving averages indicating an uptrend, though oscillators suggest overbought conditions. Fundamentally, the company reported Q2 2026 EPS of $3.02, beating estimates, and raised full-year guidance, yet faces profitability challenges with a negative net income margin of -5.96% and elevated valuation ratios like a P/E of 684.85. Recent news highlights improved biotech demand and institutional buying interest.
The outlook for CRL is cautiously optimistic, driven by earnings beats and raised guidance, but high valuation and weak profitability pose risks. Investment opportunity lies in sustained demand for drug development services, while risks include margin pressure, debt levels, and sensitivity to biotech funding cycles. The stock's proximity to all-time highs warrants monitoring for pullbacks.
Datadog (DDOG) trades at $260.78, up 11.48% in 24 hours, reflecting strong momentum after Q2 2026 earnings beat expectations with EPS of $0.65 versus $0.583 estimated. Revenue grew 36% year-over-year, and the company raised full-year 2026 guidance. Technical indicators show a bullish trend with support at $239 and resistance at $272, while high valuation multiples like a P/E of 493.56 signal premium pricing. Recent news highlights AI-driven growth but also insider selling and market sensitivity to guidance nuances.
The outlook remains positive due to robust revenue growth and AI adoption, but risks include elevated valuations and customer concentration. Analyst consensus is strongly bullish with an average price target of $288.55, though investors should monitor execution against high expectations and competitive pressures in the cloud monitoring space.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →